Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5434347 | 0.91 | RECQL (0.56) | ELANECCR1PLA2G10RECQLTP53 | |
| SCHEMBL5434666 | 0.89 | ELANE (0.55) | ELANECCR1PLA2G10PPARGPOLB | |
| SCHEMBL5438359 | 0.88 | ELANE (0.54) | ELANECCR1PLA2G10RECQLPTGER4 | |
| SCHEMBL5438329 | 0.88 | ELANE (0.59) | ELANECCR1PLA2G10RECQLPPARG | |
| SCHEMBL5441836 | 0.88 | ELANE (0.54) | ELANECCR1PLA2G10PPARG | |
| SCHEMBL5444631 | 0.86 | TP53 (0.53) | MAPK14ELANECCR1PLA2G10RECQL | |
| SCHEMBL5443070 | 0.86 | KDM4E (0.54) | MAPK14ELANECCR1PLA2G10RECQL | |
| SCHEMBL5445075 | 0.86 | ELANE (0.52) | ELANECCR1PLA2G10POLB | |
| SCHEMBL5434807 | 0.85 | ELANE (0.51) | ELANECCR1PLA2G10 | |
| SCHEMBL4686678 | 0.85 | MAPK14 (0.52) | MAPK14ELANECCR1RECQLPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010551-A1 | Quinoline derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, MPO | MAPK14 3547/4885ELANE 2/4885CCR1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.